Michael, Michael http://orcid.org/0000-0002-0593-2662
Liauw, Winston
McLachlan, Sue-Anne
Link, Emma
Matera, Annetta
Thompson, Michael
Jefford, Michael
Hicks, Rod J.
Cullinane, Carleen
Hatzimihalis, Athena
Campbell, Ian G.
Rowley, Simone
Beale, Phillip J.
Karapetis, Christos S.
Price, Timothy
Burge, Mathew E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study
https://doi.org/10.1007/s00280-021-04264-8
Funding for this research was provided by:
Australian National Health and Medical Research Council (628564)
Article History
Received: 3 December 2020
Accepted: 16 March 2021
First Online: 23 March 2021
Declarations
:
: All contributing authors have no competing financial interests in relation to the work described.
: The study was approved by the Peter MacCallum Cancer Centre Ethics Committee on the 3rd Sept 2010, followed shortly after the Institutional Ethics Committees at all other study sites. This study was to be carried out in compliance with the protocol and with adherence to Good Clinical Practice, as described in the following documents: ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996. Directive 91/507/EEC, Rules Governing Medicinal Products in the European Community. Declaration of Helsinki, concerning medical research in humans (Recommendations Guiding Physicians in Biomedical Research Involving Human Patients, Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996, Edinburgh 2000, Washington 2002; Appendix 11).